Oppenheimer initiated coverage of Rani Therapeutics with an Outperform rating and $17 price target. The company’s RaniPil is a robotic pill capable of safely and effectively delivering a range of biologics and large molecules, the analyst tells investors in a research note. The firm says Rani is going after multi-billion dollar market opportunities in endocrinology, immunology and obesity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RANI:
- Rani Therapeutics to Participate in August Investor Conferences
- Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
- Rani Therapeutics to sell 2.8M shares at $3.08 in registered diect offering
- Rani Therapeutics Reevaluates Equity Financing Strategy
- Rani Therapeutics, ProGen partner on development of oral obesity treatment